Spero Therapeutics Inc

NASDAQ:SPRO   2:51:06 PM EDT
11.65
-0.02 (-0.17%)
Products

Spero Therapeutics Announces FDA Acceptance And Priority Review Of New Drug Application For Tebipenem HBr For Treatment Of Complicated Urinary Tract Infections Including Pyelonephritis

Published: 01/03/2022 13:54 GMT
Spero Therapeutics Inc (SPRO) - Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem Hbr for Treatment of Complicated Urinary Tract Infections Including Pyelonephritis.
Spero Therapeutics - Tebipenem Hbr Granted Qualified Infectious Disease Product, Fast Track, & Priority Review Designations for These Cuti Indications.
Spero Therapeutics - Set a Prescription Drug User Fee Act (pdufa) Target Action Date of June 27, 2022 for Tebipenem Hbr.